<DOC>
	<DOCNO>NCT02349633</DOCNO>
	<brief_summary>Phase 1 : The Phase 1 study open label , multi center , multiple dose , non randomize , safety , pharmacokinetic , pharmacodynamics dose escalation study PF 06747775 single agent patient advance EGFRm NSCLC ( del19 L858R , +/ -T790M ) . Phase 2 : open label , multi-center , single arm study PF-06747775 assessment anti-tumor activity patient advance EGFRm ( del19 L858R ) advance NSCLC T790M ( del 19 T790M L858R T790M ) pharmacokinetic characterization .</brief_summary>
	<brief_title>Study For Patients With NSCLC EGFR Mutations ( Del 19 L858R +/- T790M )</brief_title>
	<detailed_description>Reason Protocol : Treatment : protocol design evaluate one intervention treat disease , syndrome condition .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion criterion ( partial list ) : Evidence histologically cytologically confirm diagnosis locally advance metastatic EGFRm ( del19 L858R ) NSCLC progress least 1 prior line therapy . Patients must least measurable lesion define RECIST V1.1 previously irradiate Patients must disease progression treatment approve EGFR TKI . In Phase 1 , patient may also receive line therapy EGFR TKI . In Phase 2 , patient may multiple line therapy , last therapy prior study treatment must approve EGFR TKI receive within 6 week prior study registration . In Phase 1 portion : In dose escalation MTD expansion portion patient must T790M positive unknown status . In PK substudies , patient EGFRm ( del 19 L858R ) T790M status eligible enroll . In Phase 2 portion : â€¢ Patients must EGFRm ( del 19 T790M L858R T790M ) NSCLC tumor Patients must least one measurable lesion define RECIST version 1.1 Tumor tissue available ( ie , formalin fix paraffin embed ( FFPE ) block 15 unstained section ( 5 micron ) . If less amount tissue available , contact sponsor . An archival specimen acceptable Phase 1 ; de novo specimen require Phase 2 . Patients must adequate bone marrow , hepatic renal function Negative serum pregnancy test Exclusion Criteria ( partial list ) Previously diagnose brain metastasis , unless patient complete treatment clinically indicate , , recover acute effect radiation therapy surgery prior study registration , discontinue corticosteroid treatment metastasis least 2 week , neurologically stable . Major surgery within 2 week prior registration Radiation therapy , exclude steriotactic radiosurgery , within 1 week prior registration . Systemic anti cancer therapy within 2 week 5 halflives ( whichever longer ) registration exclude EGFR TKIs . Patients EGFR TKIs must discontinue agent minimum : 2 day prior registration erlotinib afatinib , 3 day gefitinib part leadin single dose PF06747775 PK study ( Phase 1 Dose Escalation Single Multiple dose PK ECG Assessments ; Phase 1 Sildenafil MTD Japan PK substudies ) . Please contact Sponsor direction EGFR TKI . 5 halflives 5 day ( whichever longer ) prior registration start continuous PF06747775 dose directly ( Phase 1 PK substudies RP2D except Japan ) . Concurrent use drug strong Pglycoprotein ( Pgp ) inhibitor ( limited : dronedarone , erythromycin , indinavir , indinavir/ritonavir , itraconazole , ketoconazole , lapatinib , lopinavir/ritonavir , quinidine , rifampin , ritonavir , valspodar , verapamil , vorapaxar ) . Patients must avoid use drug know strong Pgp inhibitor duration study . therapy T790M direct agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>EGFRm - Epidermal Growth Factor Receptor Mutation</keyword>
	<keyword>Advanced EGFRm ( del19 L858R +/- T790M NSCLC</keyword>
</DOC>